Clinical Trial Update: A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase Ib/II study of QLC1401 in ER-positive, HER2-negative advanced breast cancer, examining QLC1401 with CDK4/6 or mTOR inhibitors;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors
• QLC1401
• mTOR inhibitors (mTOR inhibitors)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Advanced Breast Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING